NASDAQ:ORMP

Oramed Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ORMP

*Your capital is at risk

$3.65

+0.0500 (+1.39%)

At Close: Jun 03, 2026

Oramed Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 74.96. In total, the insiders bought 6.93M and sold 666.07K ORMP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	74.96
● Buy	6.93M shares
● Sell	666.07K shares
96% Buy Activity Strong Negative Correlation
Sell Signal Low Confidence Mar 30, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 74.96. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 30, 2026 Sell	Common Stock F-InKind	Kidron Miriam Chief Scientific Officer	Officer	435 084 Value: $1.44M
Mar 30, 2026 Sell	Common Stock F-InKind	Kidron Nadav President And CEO	CEO / President	44 818 Value: $148.3K
Mar 17, 2026 Buy	Common Stock A-Award	Gabay Avraham Chief Financial Officer	C-Suite Officer	95 889 Value: $346.2K
Mar 17, 2026 Buy	Common Stock A-Award	Kidron Nadav President And CEO	CEO / President	167 005 Value: $602.9K
Mar 17, 2026 Buy	Common Stock A-Award	Kidron Miriam Chief Scientific Officer	Officer	119 558 Value: $431.6K
Mar 17, 2026 Buy	Common Stock A-Award	Hexter Joshua COO & Cbo	C-Suite Officer	95 889 Value: $346.2K
Mar 12, 2026 Sell	Common Stock G-Gift	Kidron Nadav President And CEO	CEO / President	100 000 Value: $0
Jan 22, 2026 Buy	Common Stock M-Exempt	Hexter Joshua COO & Cbo	C-Suite Officer	19 000 Value: $63.1K
Jan 22, 2026 Buy	Performance Stock Units M-Exempt	Hexter Joshua COO & Cbo	C-Suite Officer	19 000 Value: $63.1K
Jan 22, 2026 Buy	Common Stock M-Exempt	Kidron Miriam Chief Scientific Officer	Officer	19 000 Value: $63.1K
Jan 22, 2026 Buy	Performance Stock Units M-Exempt	Kidron Miriam Chief Scientific Officer	Officer	19 000 Value: $63.1K
Jan 22, 2026 Buy	Common Stock M-Exempt	Gabay Avraham Chief Financial Officer	C-Suite Officer	19 000 Value: $63.1K
Jan 22, 2026 Buy	Performance Stock Units M-Exempt	Gabay Avraham Chief Financial Officer	C-Suite Officer	19 000 Value: $63.1K
Jan 22, 2026 Buy	Common Stock M-Exempt	Kidron Nadav President And CEO	CEO / President	109 000 Value: $361.9K
Jan 22, 2026 Buy	Performance Stock Units M-Exempt	Kidron Nadav President And CEO	CEO / President	109 000 Value: $361.9K
Jan 14, 2026 Sell	Common Stock G-Gift	Kidron Miriam Chief Scientific Officer	Officer	86 166 Value: $0
Dec 31, 2025 Buy	Common Stock A-Award	Shapiro Benjamin Director	Director	3 500 Value: $10K
Dec 31, 2025 Buy	Performance Stock Units A-Award	Hexter Joshua COO & Cbo	C-Suite Officer	19 000 Value: $54.2K
Dec 31, 2025 Buy	Common Stock A-Award	Hexter Joshua COO & Cbo	C-Suite Officer	97 328 Value: $277.4K
Dec 31, 2025 Buy	Common Stock A-Award	Hexter Joshua COO & Cbo	C-Suite Officer	115 000 Value: $327.8K
Dec 31, 2025 Buy	Performance Stock Units A-Award	Kidron Miriam Chief Scientific Officer	Officer	19 000 Value: $54.2K
Dec 31, 2025 Buy	Common Stock A-Award	Kidron Miriam Chief Scientific Officer	Officer	121 331 Value: $345.8K
Dec 31, 2025 Buy	Common Stock A-Award	Kidron Miriam Chief Scientific Officer	Officer	115 000 Value: $327.8K
Dec 31, 2025 Buy	Performance Stock Units A-Award	Kidron Nadav President And CEO	CEO / President	109 000 Value: $310.7K
Dec 31, 2025 Buy	Common Stock A-Award	Kidron Nadav President And CEO	CEO / President	232 640 Value: $663.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ORAMED PHARMACEUTICALS INC.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptid...

Read Full Profile Here